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Current standard adjuvant therapies for early breast cancer include tamoxifen and chemotherapy, depending on the patient's disease prognosis and menopausal status. Tamoxifen is the established adjuvant treatment in the post-menopausal setting. Several large trials, however, have also shown beneficial effects with oestrogen blockade in younger patients (< 50 years of age) (Cancer Research Campaign Breast Cancer Trials Group, 1992; Stewart, 1992; Fisher et al, 1996) . The Early Breast Cancer Trialists' Collaborative Group concluded that although tamoxifen may be more effective in women aged 50 years or older, younger patients may also have a significant reduction in disease recurrence (and mortality) compared with controls (Early Breast Cancer Trialists' Collaborative Group, 1992) .
Chemotherapy is usually the first treatment of choice in premenopausal patients who are unlikely to respond to endocrine therapy, such as those with oestrogen receptor (ER)-negative tumours and/or lymph node-positive disease (Harris et al, 1992) . A comprehensive meta-analysis in 1992 revealed that chemotherapy prolongs both disease-free and overall survival rates in premenopausal women with early breast cancer (Early Breast Cancer Trialists' Collaborative Group, 1992) . The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) was the most widely used combination regimen, and was undoubtedly more effective than single-agent chemotherapy at that time.
Evidence is now emerging that anthracycline-based therapies may be superior to CMF in this patient population (Browne et al, 1996; Coombes et al, 1996; Misset et al, 1996) . Luteinizing hormone-releasing hormone (LHRH) analogues offer a different approach to the management of breast cancer in premenopausal women. Goserelin has been available for the treatment of advanced breast cancer in premenopausal and perimenopausal women since the early 1 990s, and is the most extensively studied LHRH analogue in this setting. Sufficient experience has now been gained, and the results are sufficiently promising, for LHRH analogues to be considered in the treatment of early breast cancer in premenopausal women. This paper provides a brief review of the mechanism of action of goserelin and its potential benefits in early breast cancer.
MODE OF ACTION OF GOSERELIN
Goserelin acts on the hypothalamic-pituitary axis, achieving ovarian suppression by receptor down-regulation. Under physiological conditions, LHRH binds to a proportion of the LHRH receptors on the surface of pituitary cells. The occupied receptors form clusters and pass through the cell surface into the cell itself.
As not all receptors are occupied by the pulse of LHRH, and because there is constant receptor resynthesis, pituitary cells can respond to a subsequent LHRH stimulus (Clayton and Catt, 1981) . Administration of goserelin initially leads to occupation of a high proportion of LHRH receptors (Figure 1) . After a single dose, there is a short-lived rise in serum LH concentration, resulting in increased oestradiol production by the ovaries (Thomas et al, 1986) . The occupied LHRH receptors again form clusters and gradually disappear into the cell, but chronic administration of goserelin prevents the reappearance of receptors in sufficient numbers to stimulate the synthesis and secretion of LH, which falls to low levels ( Figure 2 ) (West and Baird, 1987) . This profound suppression of LH results in a decline in oestradiol to post-menopausal concentrations within approximately 21 days, and these levels are maintained with continued administration of the drug (Figure 3 ) (West and Baird, 1987) . This decrease is, however, potentially reversible, and normal ovarian function may return when goserelin treatment is stopped (West and Baird, 1987) . al, 1992, 1993 ). In the 228 evaluable patients enrolled in these open studies, the objective response rate was 36.4%, with a median response duration of 44 weeks. These results fall well within the range of the reported response rates for both conventional ovarian ablation and tamoxifen in similar patient populations (Blamey et al, 1992) . In addition, responses to goserelin, 3.6 mg, were achieved irrespective of patient age, tumour grade, ER status, previous hormone therapy or disease site, although higher response rates were seen in patients with ER-positive and/or well-differentiated tumours. In a randomized study of goserelin, 3.6 mg, with or without tamoxifen in premenopausal and perimenopausal women with locally advanced or metastatic breast cancer, 31% of goserelin-treated and 38% of goserelin plus tamoxifen-treated patients had achieved an objective response at a median of 93 weeks of follow-up (Jonat et al, 1995) . There was a significant benefit in favour of combination therapy in time to progression (23 weeks vs 28 weeks; P = 0.03), but not in survival, at a median follow-up of 117.5 weeks (127 weeks vs 140 weeks; P = 0.25).
POTENTIAL BENEFITS OF LHRH ANALOGUES IN EARLY BREAST CANCER
Goserelin has a number of potential benefits as adjuvant therapy for early breast cancer compared with other standard treatment options in premenopausal women. Tamoxifen has several disadvantages when used as adjuvant therapy in this patient population. For example, tamoxifen is known to have a stimulatory effect on the ovaries in premenopausal women, possibly by action at the hypothalamic-pituitary axis to block the negative feedback regulation of oestrogens, and has been shown to result in supraphysiological levels of oestradiol and/or ovarian cysts in certain patients (Boccardo et al, 1994; Ravdin, 1996) . In addition, tamoxifen can act as a partial oestrogen agonist in some tissues (Jordan, 1993) , Baird, 1987) CONCLUSIONS The role of LHRH analogues such as goserelin in the adjuvant and this may be associated with detrimental effects on the treatment of early breast cancer in premenopausal women remains endometrium (Barakat, 1996) and sometimes on the tumour itself to be defined. The available data indicate the potential efficacy of by tumour stimulation as tamoxifen resistance develops (DeFriend goserelin in this patient population, and it is known to be a welland Howell, 1994). Because of its mode of action and lack of tolerated, convenient agent. In addition, the ovarian suppressive agonist activity beyond the initial first few days of treatment, effects are potentially reversible, which is important in the goserelin does not stimulate the ovaries (Jordan, 1996) , and is adjuvant setting. A number of large, randomized trials have now unlikely to have a stimulatory effect on the endometrium. It is, in completed recruitment and the results will be reported over the fact, also indicated for the treatment of a wide range of benign next 12-18 months. These results will determine the role of LHRH gynaecological conditions, in which suppression of the analogues as a viable treatment option for adjuvant therapy in endometrium is required.
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